Compassionate use experience with dasatinib therapy in patients after imatinib and/or nilotinib failure

被引：0
|
作者：
Gunawardena, Bettina A. [1 ]
Schlief, Sarah [1 ]
Dempke, Wolfram [1 ]
Wnterhalter, Bernd [1 ]
机构：
[1] Bristol Myers Squibb GmbH & Co KGaA, Munich, Germany
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.4561.4561
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4561
引用
收藏
页码：212B / 212B
页数：1
相关论文
共 50 条
  • [1] Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
    Khoury, H. Jean
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Gambacorti-Passerini, Carlo
    Baccarani, Michele
    Kim, Dong-Wook
    Zaritskey, Andrey
    Countouriotis, Athena
    Besson, Nadine
    Leip, Eric
    Kelly, Virginia
    Bruemmendorf, Tim H.
    BLOOD, 2012, 119 (15) : 3403 - 3412
  • [2] Nilotinib after imatinib failure
    Pezzullo, Luca
    CLINICAL MANAGEMENT ISSUES, 2010, 4 : 17 - 21
  • [3] Experience with dasatinib and nilotinib use in pregnancy
    Barkoulas, Theodora
    Hall, Philip D.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2018, 24 (02) : 121 - 128
  • [4] REAL-LIFE COMPARISON OF DASATINIB AND NILOTINIB AS SECOND-LINE THERAPY AFTER IMATINIB FAILURE FOR CHRONIC PHASE CML
    Tiribelli, M.
    Bonifacio, M.
    Binotto, G.
    Iurlo, A.
    Cibien, F.
    Maino, E.
    Guella, A.
    Festini, G.
    Minotto, C.
    De Biasi, E.
    De Marchi, F.
    Scaffidi, L.
    Frison, L.
    Bucelli, C.
    Medeot, M.
    Calistri, E.
    Sancetta, R.
    Stulle, M.
    Krampera, M.
    Gherlinzoni, F.
    Semenzato, G.
    Ambrosetti, A.
    Fanin, R.
    HAEMATOLOGICA, 2016, 101 : 237 - 238
  • [5] Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy
    F J Giles
    E Abruzzese
    G Rosti
    D-W Kim
    R Bhatia
    A Bosly
    S Goldberg
    G L S Kam
    M Jagasia
    W Mendrek
    T Fischer
    T Facon
    U Dünzinger
    D Marin
    M C Mueller
    Y Shou
    N J Gallagher
    R A Larson
    F-X Mahon
    M Baccarani
    J Cortes
    H M Kantarjian
    Leukemia, 2010, 24 : 1299 - 1301
  • [6] Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy
    Giles, F. J.
    Abruzzese, E.
    Rosti, G.
    Kim, D-W
    Bhatia, R.
    Bosly, A.
    Goldberg, S.
    Kam, G. L. S.
    Jagasia, M.
    Mendrek, W.
    Fischer, T.
    Facon, T.
    Duenzinger, U.
    Marin, D.
    Mueller, M. C.
    Shou, Y.
    Gallagher, N. J.
    Larson, R. A.
    Mahon, F-X
    Baccarani, M.
    Cortes, J.
    Kantarjian, H. M.
    LEUKEMIA, 2010, 24 (07) : 1299 - 1301
  • [7] Nilotinib therapy after resistance to imatinib
    Porrini, Raffaele
    Montefusco, Enrico
    CLINICAL MANAGEMENT ISSUES, 2012, 6 : 7 - 10
  • [8] CLINICAL EXPERIENCE OF BOSUTINIB UNDER COMPASIONATE USE PROGRAM IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH RESISTANCE OR INTOLERANCE TO IMATINIB, DASATINIB AND NILOTINIB
    Garcia-Gutierrez, V.
    Maestro, B.
    Cervantes, F.
    Lopez Lorenzo, J. L.
    Martin Mateos, M. L.
    Alvarez, A.
    Iglesias Perez, A.
    Romo Collado, A.
    Fernandez Fernandez, A.
    Bautista, G.
    Portero, A.
    Cuevas, B.
    Ruiz, C.
    Amutio, E.
    Del Orbe, R. D. A.
    Romero, E.
    Ortega, F.
    Mata, I.
    Tallon, J.
    Garcia Garay, M. D. C.
    Ramirez Sanchez, M. J.
    de las Heras, N.
    Giraldo, P.
    Bobillo, S.
    Steegmann, J. L.
    HAEMATOLOGICA, 2014, 99 : 337 - 338
  • [9] PREDICTIVE FACTORS OF STABLE DEEP MOLECULAR RESPONSE IN CHRONIC PHASE CML PATIENTS TREATED WITH DASATINIB OR NILOTINIB AFTER IMATINIB FAILURE
    Bonifacio, M.
    Binotto, G.
    Tiribelli, M.
    Scaffidi, L.
    Iurlo, A.
    Cibien, F.
    Maino, E.
    Guella, A.
    Festini, G.
    Minotto, C.
    De Biasi, E.
    Frison, L.
    De Marchi, F.
    Medeot, M.
    Bucelli, C.
    Calistri, E.
    Stulle, M.
    Gherlinzoni, F.
    Cortelezzi, A.
    Fanin, R.
    Semenzato, G.
    Krampera, M.
    Pizzolo, G.
    Ambrosetti, A.
    HAEMATOLOGICA, 2016, 101 : 735 - 735
  • [10] Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib
    Minami, Mariko
    Arita, Takeshi
    Iwasaki, Hiromi
    Muta, Tsuyoshi
    Aoki, Takatoshi
    Aoki, Kenichi
    Yamasaki, Satoshi
    Matsushima, Takamitsu
    Kato, Koji
    Takenaka, Katsuto
    Tanimoto, Kazuki
    Kamimura, Tomohiko
    Ogawa, Ryosuke
    Akashi, Koichi
    Miyamoto, Toshihiro
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 177 (04) : 578 - 587
12345